Novo Nordisk: Life science power in EU industrial policy revision has been dimmed by Brexit
Europe’s life science industry relied heavily on UK leadership, says a Novo Nordisk representative, lamenting the loss of a pharmaceutical powerhouse when the EU revisits its industry policy.
by peter thomsen, eu correspondent for watch medier, translated by daniel pedersen
LONDON – The UK’s absence in the EU has meant more for the Union than just seeing the European Medicines Agency (EMA) move from London to Amsterdam.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk CEO on EU pharma reform: "A lose, lose, lose"
For subscribers
Novo CEO spies new pricing model in EU
For subscribers
.jpg&w=384&q=75)
